Stockreport

Mitsubishi Tanabe Pharma America Presents Final Results from the Global, Phase 3b MT-1186-A02 Post-marketing Study of RADICAVA® (edaravone) in ALS [Yahoo! Finance]

MITSUBISHI CH GRP U/ADR  (MTLHY) 
NASDAQ:AMEX Investor Relations: mitsubishichem-hd.co.jp/english/ir
PDF the global, multi-center, double-blind, Phase 3b MT-1186-A02 study of oral edaravone in amyotrophic lateral sclerosis (ALS). Final results showed the daily dosing regime [Read more]